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ABSTRACT 
The overall aim this study was to examine the possibility of using immobilised 
polypeptide chains to fractionate/separate Glycosaminoglycans (GAG's) from 
mixtures. 
ii 
Initially individual samples of three GAG classes (chondroitin sulphate, dermatan 
sulphate and heparin) were characterised to establish purity and provide basic 
information. Once these samples had been characterised the samples were treated as 
standards. 
Three short poly-I-lysine (PLL) chains with defined length and orientation were 
synthesized. As a control a PLL chain with 633 residues was immobilised. The 
interaction of the GAG standards with these resins did not replicate published 
solution binding behaviour of longer PLL chains. This suggested a different mode of 
binding. The interaction of two lengths of PLL (126 and 633 residues) and the K8G 
peptide with the GAG standards in solution was investigated. These studies 
demonstrated that the mode of binding of GAG's to short PLL chains was radically 
different to the earlier reported solution binding studies. B-Strand dominates with the 
short PLL chains instead of a-helix established in the published solution binding 
studies. 
The interaction of two peptides PCI (264-283) and thrombospondin peptide with the 
GAG standards was studied using circular dichroism spectroscopy. In the case of the 
PCI peptide, each GAG induced different secondary structures. Chondroitin sulphate 
and heparin induced an a-helix, whereas dermatan sulphate gave B-strands. Heparin 
and dermatan sulphate induced double the amount of secondary structure compared 
to chondroitin sulphate. The strength of the interaction of GAG's with the peptide 
was also measured by the concentration of salt required to dissociate 50% of the 
complex. The figures for dermatan sulphate and heparin were found to be 0.1 and 
0.3 M salt respectively. The binding of the GAG standards to the thrombospondin 
• 
iii 
peptide did not elicit any detectable change in conformation of the peptide. 
Critical examination of published material on the interaction of GAG's (principally 
heparin) with short peptides, prompted the writer to propose two new complementary 
models. The first model examines binding in terms of the conformation of the 
peptide induced by binding to the GAG. It is composed of three components, the 
periodicity of polar and nonpolar residues within the peptide sequence, the spacing of 
pairs of basic residues and the spacing of pairs of acidic and basic residues. This 
model is successfully able to rationalise the binding behaviour of a number of 
GAG/peptide interactions in terms of the dominant secondary structure and the 
biological activity. The model is able to make a number of specific predictions. The 
second model examines the strength of the interaction between heparin and peptides 
containing the proposed consensus sequences for GAG binding sites. A significant 
correlation between the binding strength and an attribute derived from the sequence 
of the peptide was found using only one assumption. The assumption was that the 
peptides in the correlation bound to heparin with significant levels of B-strand. 
For the first time it is possible to rationalise the behaviour of GAG/peptide 
interactions in a coherent manner. The design of peptides that are capable of binding 
to specific GAG's now seems possible. 
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Abbreviations 
a Alpha helix 
B Beta sheet 
en Carbon thirteen 
cs Chondroitin sulphate 
C4S Chondroitin-4-sulphate 
C6S Chondroitin-6-sulphate 
CD Circular dichroism 






GlcNAc N acety lglucosamine 
GlcNS Glucosamine-Nsulphate 
GlcNS(5S) Glucosamine-Nsulphate-50sulphate 
GlcN(6S03) Glucosamine-N sulphate-60sulphate 
GluA Glucuronic acid 
Hep Heparin 
HexA Hexuronic acid 
HS Heparan sulphate 
Ido2S Iduronic acid-20sulphate 
IdoA Iduronic acid 
Neer Number of theoretical plates 
PLA Poly-L-arginine 
PLL Poly-L-lysine 
R Random coil 
